**Data supplement**

**Title:** Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study

**Authors:** Kristina Crothers,1,2 Rian DeFaccio,1 Janet Tate,3 Patrick R. Alba,4 Matthew Goetz,5 Barbara Jones,4 Joseph T. King, Jr., 3 Vincent Marconi,6 Michael E. Ohl,7 Christopher T. Rentsch,8 Maria C. Rodriguez-Barradas,9 Shahida Shahrir,2 Amy C. Justice,3,10 and Kathleen M. Akgün3

Veterans Aging Cohort Study Clinical COVID-19 Working Group

1. Veterans Affairs (VA) Puget Sound Health Care System, Seattle, WA, USA
2. Department of Medicine, University of Washington, Seattle, WA, USA
3. VA Connecticut Health Care System and Yale University School of Medicine, New Haven, CT, USA
4. VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, USA
5. VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
6. Atlanta VA Medical Center, and Emory University, Atlanta, GA, USA
7. Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA
8. Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK
9. Michael E. DeBakey VAMC and Baylor College of Medicine, Houston, TX, USA
10. Yale School of Public Health, New Haven, CT, USA

**Supplemental Table 1. Unweighted and propensity weighted pseudo populations**

**A. Unweighted population**

| Corticosteroids | No Oxygen | | | Nasal Canula | | | Combined Cohort | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| No | Yes | SMD | No | Yes | SMD | No | Yes | SMD |
| **Cohort, n** | 2421 | 595 |  | 988 | 2793 |  | 3409 | 3388 |  |
| **Age, (%)** |  |  |  |  |  |  |  |  |  |
| <50 | 273 (11.3) | 59 ( 9.9) | -0.014 | 70 ( 7.1) | 261 ( 9.3) | 0.023 | 343 (10.1) | 320 ( 9.4) | -0.006 |
| 50-59 | 296 (12.2) | 90 (15.1) | 0.029 | 125 (12.7) | 344 (12.3) | -0.003 | 421 (12.3) | 434 (12.8) | 0.005 |
| 60-69 | 551 (22.8) | 138 (23.2) | 0.004 | 222 (22.5) | 647 (23.2) | 0.007 | 773 (22.7) | 785 (23.2) | 0.005 |
| 70-79 | 772 (31.9) | 195 (32.8) | 0.009 | 341 (34.5) | 1048 (37.5) | 0.030 | 1113 (32.6) | 1243 (36.7) | 0.040 |
| 80+ | 529 (21.9) | 113 (19.0) | -0.029 | 230 (23.3) | 493 (17.7) | -0.056 | 759 (22.3) | 606 (17.9) | -0.044 |
| **Sex: Male, (%)** | 2287 (94.5) | 562 (94.5) | 0.000 | 931 (94.2) | 2644 (94.7) | 0.004 | 3218 (94.4) | 3206 (94.6) | 0.002 |
| **Race, (%)** |  |  |  |  |  |  |  |  |  |
| White, non-Hispanic | 1240 (51.2) | 321 (53.9) | 0.027 | 526 (53.2) | 1589 (56.9) | 0.037 | 1766 (51.8) | 1910 (56.4) | 0.046 |
| Black, non-Hispanic | 765 (31.6) | 159 (26.7) | -0.049 | 299 (30.3) | 678 (24.3) | -0.060 | 1064 (31.2) | 837 (24.7) | -0.065 |
| Hispanic | 213 ( 8.8) | 61 (10.3) | 0.015 | 78 ( 7.9) | 290 (10.4) | 0.025 | 291 ( 8.5) | 351 (10.4) | 0.018 |
| Other | 123 ( 5.1) | 28 ( 4.7) | -0.004 | 55 ( 5.6) | 152 ( 5.4) | -0.001 | 178 ( 5.2) | 180 ( 5.3) | 0.001 |
| Unknown | 80 ( 3.3) | 26 ( 4.4) | 0.011 | 30 ( 3.0) | 84 ( 3.0) | 0.000 | 110 ( 3.2) | 110 ( 3.2) | 0.000 |
| **Phase (Admission Date) , (%)** |  |  |  |  |  |  |  |  |  |
| 1: June 7 - July 11 | 430 (17.8) | 51 ( 8.6) | -0.092 | 289 (29.3) | 270 ( 9.7) | -0.196 | 719 (21.1) | 321 ( 9.5) | -0.116 |
| 2: July 12 - Aug. 15 | 456 (18.8) | 79 (13.3) | -0.056 | 201 (20.3) | 490 (17.5) | -0.028 | 657 (19.3) | 569 (16.8) | -0.025 |
| 3: Aug. 16 - Oct. 17 | 525 (21.7) | 139 (23.4) | 0.017 | 201 (20.3) | 587 (21.0) | 0.007 | 726 (21.3) | 726 (21.4) | 0.001 |
| 4: Oct. 18 - Dec. 5 | 1010 (41.7) | 326 (54.8) | 0.131 | 297 (30.1) | 1446 (51.8) | 0.217 | 1307 (38.3) | 1772 (52.3) | 0.140 |
| **Site Dexamethasone Prescribing, (%)** |  |  |  |  |  |  |  |  |  |
| Low | 690 (28.5) | 84 (14.1) | -0.144 | 295 (29.9) | 421 (15.1) | -0.148 | 985 (28.9) | 505 (14.9) | -0.140 |
| Medium | 1473 (60.8) | 358 (60.2) | -0.007 | 572 (57.9) | 1665 (59.6) | 0.017 | 2045 (60.0) | 2023 (59.7) | -0.003 |
| High | 258 (10.7) | 153 (25.7) | 0.151 | 121 (12.2) | 707 (25.3) | 0.131 | 379 (11.1) | 860 (25.4) | 0.143 |
| **Smoking Status, (%)** |  |  |  |  |  |  |  |  |  |
| Never Smoked | 842 (34.8) | 203 (34.1) | -0.007 | 337 (34.1) | 939 (33.6) | -0.005 | 1179 (34.6) | 1142 (33.7) | -0.009 |
| Former Smoker | 908 (37.5) | 269 (45.2) | 0.077 | 411 (41.6) | 1305 (46.7) | 0.051 | 1319 (38.7) | 1574 (46.5) | 0.078 |
| Current Smoker | 626 (25.9) | 112 (18.8) | -0.070 | 211 (21.4) | 506 (18.1) | -0.032 | 837 (24.6) | 618 (18.2) | -0.063 |
| Unknown | 45 ( 1.9) | 11 ( 1.8) | 0.000 | 29 ( 2.9) | 43 ( 1.5) | -0.014 | 74 ( 2.2) | 54 ( 1.6) | -0.006 |
| **AUDIT-C Score (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 1489 (61.5) | 369 (62.0) | 0.005 | 645 (65.3) | 1767 (63.3) | -0.020 | 2134 (62.6) | 2136 (63.0) | 0.004 |
| 1 – 3 | 481 (19.9) | 132 (22.2) | 0.023 | 204 (20.6) | 674 (24.1) | 0.035 | 685 (20.1) | 806 (23.8) | 0.037 |
| 4 – 7 | 167 ( 6.9) | 34 ( 5.7) | -0.012 | 39 ( 3.9) | 147 ( 5.3) | 0.013 | 206 ( 6.0) | 181 ( 5.3) | -0.007 |
| 8 + | 81 ( 3.3) | 15 ( 2.5) | -0.008 | 20 ( 2.0) | 43 ( 1.5) | -0.005 | 101 ( 3.0) | 58 ( 1.7) | -0.013 |
| Unknown | 203 ( 8.4) | 45 ( 7.6) | -0.008 | 80 ( 8.1) | 162 ( 5.8) | -0.023 | 283 ( 8.3) | 207 ( 6.1) | -0.022 |
| **Comorbidities** |  |  |  |  |  |  |  |  |  |
| Myocardial Infarction (%) | 208 ( 8.6) | 36 ( 6.1) | -0.025 | 89 ( 9.0) | 216 ( 7.7) | -0.013 | 297 ( 8.7) | 252 ( 7.4) | -0.013 |
| Congestive Heart Failure (%) | 468 (19.3) | 102 (17.1) | -0.022 | 271 (27.4) | 534 (19.1) | -0.083 | 739 (21.7) | 636 (18.8) | -0.029 |
| Cerebrovascular Disease (%) | 461 (19.0) | 79 (13.3) | -0.058 | 188 (19.0) | 418 (15.0) | -0.041 | 649 (19.0) | 497 (14.7) | -0.044 |
| Dementia (%) | 467 (19.3) | 59 ( 9.9) | -0.094 | 172 (17.4) | 252 ( 9.0) | -0.084 | 639 (18.7) | 311 ( 9.2) | -0.096 |
| Chronic Obstructive Pulmonary Disease (%) | 546 (22.6) | 168 (28.2) | 0.057 | 306 (31.0) | 923 (33.0) | 0.021 | 852 (25.0) | 1091 (32.2) | 0.072 |
| Rheumatoid Arthritis (%) | 34 ( 1.4) | 9 ( 1.5) | 0.001 | 14 ( 1.4) | 49 ( 1.8) | 0.003 | 48 ( 1.4) | 58 ( 1.7) | 0.003 |
| Peptic ulcer (%) | 72 ( 3.0) | 9 ( 1.5) | -0.015 | 25 ( 2.5) | 55 ( 2.0) | -0.006 | 97 ( 2.8) | 64 ( 1.9) | -0.010 |
| Liver disease, mild (%) | 335 (13.8) | 66 (11.1) | -0.027 | 100 (10.1) | 265 ( 9.5) | -0.006 | 435 (12.8) | 331 ( 9.8) | -0.030 |
| Diabetes, Uncomplicated (%) | 1054 (43.5) | 278 (46.7) | 0.032 | 474 (48.0) | 1369 (49.0) | 0.010 | 1528 (44.8) | 1647 (48.6) | 0.038 |
| Diabetes, Complicated (%) | 704 (29.1) | 168 (28.2) | -0.008 | 318 (32.2) | 819 (29.3) | -0.029 | 1022 (30.0) | 987 (29.1) | -0.008 |
| Hemi or paraplegia (%) | 84 ( 3.5) | 10 ( 1.7) | -0.018 | 36 ( 3.6) | 52 ( 1.9) | -0.018 | 120 ( 3.5) | 62 ( 1.8) | -0.017 |
| Liver disease, moderate-severe (%) | 56 ( 2.3) | 9 ( 1.5) | -0.008 | 13 ( 1.3) | 32 ( 1.1) | -0.002 | 69 ( 2.0) | 41 ( 1.2) | -0.008 |
| Metastatic cancer (%) | 56 ( 2.3) | 6 ( 1.0) | -0.013 | 16 ( 1.6) | 46 ( 1.6) | 0.000 | 72 ( 2.1) | 52 ( 1.5) | -0.006 |
| HIV (%) | 32 ( 1.3) | 10 ( 1.7) | 0.004 | 13 ( 1.3) | 20 ( 0.7) | -0.006 | 45 ( 1.3) | 30 ( 0.9) | -0.004 |
| Renal disease (%) | 610 (25.2) | 140 (23.5) | -0.017 | 284 (28.7) | 656 (23.5) | -0.053 | 894 (26.2) | 796 (23.5) | -0.027 |
| **Charlson Comorbidities Count (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 499 (20.6) | 134 (22.5) | 0.019 | 179 (18.1) | 518 (18.5) | 0.004 | 678 (19.9) | 652 (19.2) | -0.006 |
| 1 - 2 | 737 (30.4) | 200 (33.6) | 0.032 | 278 (28.1) | 934 (33.4) | 0.053 | 1015 (29.8) | 1134 (33.5) | 0.037 |
| 3 - 4 | 529 (21.9) | 131 (22.0) | 0.002 | 235 (23.8) | 702 (25.1) | 0.013 | 764 (22.4) | 833 (24.6) | 0.022 |
| 5 + | 656 (27.1) | 130 (21.8) | -0.052 | 296 (30.0) | 639 (22.9) | -0.071 | 952 (27.9) | 769 (22.7) | -0.052 |
| **Number of Doctors (prior year) (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 1057 (43.7) | 250 (42.0) | -0.016 | 395 (40.0) | 1075 (38.5) | -0.015 | 1452 (42.6) | 1325 (39.1) | -0.035 |
| 1 | 653 (27.0) | 182 (30.6) | 0.036 | 246 (24.9) | 780 (27.9) | 0.030 | 899 (26.4) | 962 (28.4) | 0.020 |
| 2 - 4 | 645 (26.6) | 155 (26.1) | -0.006 | 316 (32.0) | 879 (31.5) | -0.005 | 961 (28.2) | 1034 (30.5) | 0.023 |
| 5 + | 66 ( 2.7) | 8 ( 1.3) | -0.014 | 31 ( 3.1) | 59 ( 2.1) | -0.010 | 97 ( 2.8) | 67 ( 2.0) | -0.009 |
| **Specialty clinics attended**  Cardiology **(%)** | 580 (24.0) | 147 (24.7) | 0.007 | 296 (30.0) | 759 (27.2) | -0.028 | 876 (25.7) | 906 (26.7) | 0.010 |
| Coagulation (%) | 38 ( 1.6) | 13 ( 2.2) | 0.006 | 21 ( 2.1) | 31 ( 1.1) | -0.010 | 59 ( 1.7) | 44 ( 1.3) | -0.004 |
| Pacemaker (%) | 93 ( 3.8) | 20 ( 3.4) | -0.005 | 48 ( 4.9) | 70 ( 2.5) | -0.024 | 141 ( 4.1) | 90 ( 2.7) | -0.015 |
| Dialysis (%) | 32 ( 1.3) | 5 ( 0.8) | -0.005 | 32 ( 3.2) | 33 ( 1.2) | -0.021 | 64 ( 1.9) | 38 ( 1.1) | -0.008 |
| Gastoenterology (%) | 203 ( 8.4) | 61 (10.3) | 0.019 | 86 ( 8.7) | 292 (10.5) | 0.018 | 289 ( 8.5) | 353 (10.4) | 0.019 |
| Hepatology (%) | 97 ( 4.0) | 10 ( 1.7) | -0.023 | 30 ( 3.0) | 64 ( 2.3) | -0.007 | 127 ( 3.7) | 74 ( 2.2) | -0.015 |
| Homeless (%) | 199 ( 8.2) | 30 ( 5.0) | -0.032 | 58 ( 5.9) | 93 ( 3.3) | -0.025 | 257 ( 7.5) | 123 ( 3.6) | -0.039 |
| Prophylactic Anticoagulants | 1267 (52.3) | 332 (55.8) | 0.035 | 523 (52.9) | 1643 (58.8) | 0.059 | 1790 (52.5) | 1975 (58.3) | 0.058 |
| **Co-medications** |  |  |  |  |  |  |  |  |  |
| Remdesivir, 1st 48 hours (%) | 174 ( 7.2) | 257 (43.2) | 0.360 | 211 (21.4) | 2001 (71.6) | 0.503 | 385 (11.3) | 2258 (66.6) | 0.554 |
| **Laboratory Results** |  |  |  |  |  |  |  |  |  |
| Albumin, g/dL (%) |  |  |  |  |  |  |  |  |  |
| 3.5 + | 1050 (43.4) | 218 (36.6) | -0.067 | 305 (30.9) | 781 (28.0) | -0.029 | 1355 (39.7) | 999 (29.5) | -0.103 |
| 3 - 3.49 | 719 (29.7) | 203 (34.1) | 0.044 | 344 (34.8) | 1005 (36.0) | 0.012 | 1063 (31.2) | 1208 (35.7) | 0.045 |
| < 3 | 478 (19.7) | 151 (25.4) | 0.056 | 285 (28.8) | 928 (33.2) | 0.044 | 763 (22.4) | 1079 (31.8) | 0.095 |
| Missing | 174 ( 7.2) | 23 ( 3.9) | -0.033 | 54 ( 5.5) | 79 ( 2.8) | -0.026 | 228 ( 6.7) | 102 ( 3.0) | -0.037 |
| Alanine aminotransferase, IU/L (%) |  |  |  |  |  |  |  |  |  |
| < 20 | 784 (32.4) | 148 (24.9) | -0.075 | 290 (29.4) | 578 (20.7) | -0.087 | 1074 (31.5) | 726 (21.4) | -0.101 |
| 20 - 39 | 938 (38.7) | 242 (40.7) | 0.019 | 418 (42.3) | 1201 (43.0) | 0.007 | 1356 (39.8) | 1443 (42.6) | 0.028 |
| 40 + | 533 (22.0) | 199 (33.4) | 0.114 | 227 (23.0) | 977 (35.0) | 0.120 | 760 (22.3) | 1176 (34.7) | 0.124 |
| Missing | 166 ( 6.9) | 6 ( 1.0) | -0.058 | 53 ( 5.4) | 37 ( 1.3) | -0.040 | 219 ( 6.4) | 43 ( 1.3) | -0.052 |
| Asparate aminostransferase, IU/L (%) |  |  |  |  |  |  |  |  |  |
| < 20 | 654 (27.0) | 65 (10.9) | -0.161 | 199 (20.1) | 218 ( 7.8) | -0.123 | 853 (25.0) | 283 ( 8.4) | -0.167 |
| 20 - 39 | 1098 (45.4) | 279 (46.9) | 0.015 | 444 (44.9) | 1218 (43.6) | -0.013 | 1542 (45.2) | 1497 (44.2) | -0.010 |
| 40 + | 669 (27.6) | 251 (42.2) | 0.146 | 345 (34.9) | 1357 (48.6) | 0.137 | 1014 (29.7) | 1608 (47.5) | 0.177 |
| Creatinine, mg/dL (%) |  |  |  |  |  |  |  |  |  |
| < 1.2 | 1223 (50.5) | 277 (46.6) | -0.040 | 423 (42.8) | 1324 (47.4) | 0.046 | 1646 (48.3) | 1601 (47.3) | -0.010 |
| 1.2 – 1.99 | 797 (32.9) | 244 (41.0) | 0.081 | 374 (37.9) | 1048 (37.5) | -0.003 | 1171 (34.4) | 1292 (38.1) | 0.038 |
| 2 + | 360 (14.9) | 74 (12.4) | -0.024 | 186 (18.8) | 421 (15.1) | -0.038 | 546 (16.0) | 495 (14.6) | -0.014 |
| Missing | 41 ( 1.7) | 0 ( 0.0) | -0.017 | 5 ( 0.5) | 0 ( 0.0) | -0.005 | 46 ( 1.3) | 0 ( 0.0) | -0.013 |
| Fibrosis-4 Index (%) |  |  |  |  |  |  |  |  |  |
| < 1.45 | 550 (22.7) | 129 (21.7) | -0.010 | 162 (16.4) | 411 (14.7) | -0.017 | 712 (20.9) | 540 (15.9) | -0.049 |
| 1.45 – 3.25 | 994 (41.1) | 239 (40.2) | -0.009 | 394 (39.9) | 1260 (45.1) | 0.052 | 1388 (40.7) | 1499 (44.2) | 0.035 |
| 3.25 + | 697 (28.8) | 220 (37.0) | 0.082 | 377 (38.2) | 1081 (38.7) | 0.005 | 1074 (31.5) | 1301 (38.4) | 0.069 |
| Missing | 180 ( 7.4) | 7 ( 1.2) | -0.063 | 55 ( 5.6) | 41 ( 1.5) | -0.041 | 235 ( 6.9) | 48 ( 1.4) | -0.055 |
| Lactate, mmol/L (%) |  |  |  |  |  |  |  |  |  |
| 1\_1.2 | 361 (14.9) | 118 (19.8) | 0.049 | 172 (17.4) | 496 (17.8) | 0.003 | 533 (15.6) | 614 (18.1) | 0.025 |
| 2\_1.2LT2 | 514 (21.2) | 172 (28.9) | 0.077 | 254 (25.7) | 930 (33.3) | 0.076 | 768 (22.5) | 1102 (32.5) | 0.100 |
| 3\_GE2 | 250 (10.3) | 96 (16.1) | 0.058 | 151 (15.3) | 413 (14.8) | -0.005 | 401 (11.8) | 509 (15.0) | 0.033 |
| Missing | 1296 (53.5) | 209 (35.1) | -0.184 | 411 (41.6) | 954 (34.2) | -0.074 | 1707 (50.1) | 1163 (34.3) | -0.157 |
| Platelet count per microL (%) |  |  |  |  |  |  |  |  |  |
| 150 or higher | 1631 (67.4) | 401 (67.4) | 0.000 | 613 (62.0) | 1893 (67.8) | 0.057 | 2244 (65.8) | 2294 (67.7) | 0.019 |
| < 150 | 744 (30.7) | 194 (32.6) | 0.019 | 371 (37.6) | 897 (32.1) | -0.054 | 1115 (32.7) | 1091 (32.2) | -0.005 |
| Missing | 46 ( 1.9) | 0 ( 0.0) | -0.019 | 4 ( 0.4) | 3 ( 0.1) | -0.003 | 50 ( 1.5) | 3 ( 0.1) | -0.014 |
| Total bilirubin, mg/dL (%) |  |  |  |  |  |  |  |  |  |
| < 1 | 1799 (74.3) | 456 (76.6) | 0.023 | 734 (74.3) | 2089 (74.8) | 0.005 | 2533 (74.3) | 2545 (75.1) | 0.008 |
| 1 - 1.2 | 182 ( 7.5) | 49 ( 8.2) | 0.007 | 94 ( 9.5) | 278 (10.0) | 0.004 | 276 ( 8.1) | 327 ( 9.7) | 0.016 |
| 1.2 + | 290 (12.0) | 86 (14.5) | 0.025 | 111 (11.2) | 393 (14.1) | 0.028 | 401 (11.8) | 479 (14.1) | 0.024 |
| Missing | 150 ( 6.2) | 4 ( 0.7) | -0.055 | 49 ( 5.0) | 33 ( 1.2) | -0.038 | 199 ( 5.8) | 37 ( 1.1) | -0.047 |
| White Blood Count per microL (%) |  |  |  |  |  |  |  |  |  |
| 4-10 | 1494 (61.7) | 274 (46.1) | -0.157 | 564 (57.1) | 1261 (45.1) | -0.119 | 2058 (60.4) | 1535 (45.3) | -0.151 |
| <4 | 606 (25.0) | 202 (33.9) | 0.089 | 269 (27.2) | 821 (29.4) | 0.022 | 875 (25.7) | 1023 (30.2) | 0.045 |
| >10 | 321 (13.3) | 119 (20.0) | 0.067 | 155 (15.7) | 711 (25.5) | 0.098 | 476 (14.0) | 830 (24.5) | 0.105 |
| C-reactive protein measured (%) | 1281 (52.9) | 415 (69.7) | 0.168 | 563 (57.0) | 1828 (65.4) | 0.085 | 1844 (54.1) | 2243 (66.2) | 0.121 |
| D-dimer measured (%) | 1712 (70.7) | 486 (81.7) | 0.110 | 775 (78.4) | 2354 (84.3) | 0.058 | 2487 (73.0) | 2840 (83.8) | 0.109 |
| **Viral Signs** |  |  |  |  |  |  |  |  |  |
| Highest Temperature (F) (%) |  |  |  |  |  |  |  |  |  |
| < 99 | 1051 (43.4) | 198 (33.3) | -0.101 | 279 (28.2) | 816 (29.2) | 0.010 | 1330 (39.0) | 1014 (29.9) | -0.091 |
| 99 - 100 | 606 (25.0) | 140 (23.5) | -0.015 | 230 (23.3) | 644 (23.1) | -0.002 | 836 (24.5) | 784 (23.1) | -0.014 |
| 100 - 102 | 537 (22.2) | 183 (30.8) | 0.086 | 319 (32.3) | 878 (31.4) | -0.009 | 856 (25.1) | 1061 (31.3) | 0.062 |
| 102 + | 220 ( 9.1) | 71 (11.9) | 0.028 | 158 (16.0) | 438 (15.7) | -0.003 | 378 (11.1) | 509 (15.0) | 0.039 |
| Missing | 7 ( 0.3) | 3 ( 0.5) | 0.002 | 2 ( 0.2) | 17 ( 0.6) | 0.004 | 9 ( 0.3) | 20 ( 0.6) | 0.003 |
| Mean Arterial Pressure, mmHg (%) |  |  |  |  |  |  |  |  |  |
| < 60 | 63 ( 2.6) | 9 ( 1.5) | -0.011 | 37 ( 3.7) | 46 ( 1.6) | -0.021 | 100 ( 2.9) | 55 ( 1.6) | -0.013 |
| 60 – 69 | 322 (13.3) | 51 ( 8.6) | -0.047 | 148 (15.0) | 341 (12.2) | -0.028 | 470 (13.8) | 392 (11.6) | -0.022 |
| 70 – 89 | 1575 (65.1) | 401 (67.4) | 0.023 | 643 (65.1) | 1906 (68.2) | 0.032 | 2218 (65.1) | 2307 (68.1) | 0.030 |
| 90 + | 455 (18.8) | 133 (22.4) | 0.036 | 159 (16.1) | 486 (17.4) | 0.013 | 614 (18.0) | 619 (18.3) | 0.003 |
| Missing | 6 ( 0.2) | 1 ( 0.2) | -0.001 | 1 ( 0.1) | 14 ( 0.5) | 0.004 | 7 ( 0.2) | 15 ( 0.4) | 0.002 |
| Lowest Oxygen Saturation (%) |  |  |  |  |  |  |  |  |  |
| < 88 | 30 ( 1.2) | 11 ( 1.8) | 0.006 | 78 ( 7.9) | 338 (12.1) | 0.042 | 108 ( 3.2) | 349 (10.3) | 0.071 |
| 88 - 92 | 630 (26.0) | 263 (44.2) | 0.182 | 489 (49.5) | 1686 (60.4) | 0.109 | 1119 (32.8) | 1949 (57.5) | 0.247 |
| 93 - 95 | 1198 (49.5) | 238 (40.0) | -0.095 | 311 (31.5) | 580 (20.8) | -0.107 | 1509 (44.3) | 818 (24.1) | -0.201 |
| 96 + | 508 (21.0) | 70 (11.8) | -0.092 | 92 ( 9.3) | 119 ( 4.3) | -0.051 | 600 (17.6) | 189 ( 5.6) | -0.120 |
| Missing | 55 ( 2.3) | 13 ( 2.2) | -0.001 | 18 ( 1.8) | 70 ( 2.5) | 0.007 | 73 ( 2.1) | 83 ( 2.4) | 0.003 |

**B. Propensity weighted pseudo population estimating the average treatment effect in the entire population (ATE)**

| Characteristics | No Oxygen | | | Nasal Canula | | | Combined Cohort | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| No | Yes | SMD | No | No | Yes | SMD | Yes | No |
| **Cohort, n** | 2979.1 | 2108.3 |  | 2585.7 | 3755.7 |  | 5796.7 | 6144.2 |  |
| **Age, (%)** |  |  |  |  |  |  |  |  |  |
| <50 | 324.5 (10.9) | 192.7 ( 9.1) | -0.018 | 205.9 ( 8.0) | 339.7 ( 9.0) | 0.011 | 514.4 ( 8.9) | 572.8 ( 9.3) | 0.004 |
| 50-59 | 368.8 (12.4) | 263.4 (12.5) | 0.001 | 314.0 (12.1) | 473.6 (12.6) | 0.005 | 683.7 (11.8) | 761.0 (12.4) | 0.006 |
| 60-69 | 686.9 (23.1) | 536.7 (25.5) | 0.024 | 569.7 (22.0) | 842.4 (22.4) | 0.004 | 1329.2 (22.9) | 1390.5 (22.6) | -0.003 |
| 70-79 | 964.0 (32.4) | 719.7 (34.1) | 0.018 | 938.2 (36.3) | 1384.5 (36.9) | 0.006 | 2055.2 (35.5) | 2247.7 (36.6) | 0.011 |
| 80+ | 634.9 (21.3) | 395.7 (18.8) | -0.025 | 557.9 (21.6) | 715.4 (19.0) | -0.025 | 1214.1 (20.9) | 1172.2 (19.1) | -0.019 |
| **Sex: Male, (%)** | 2811.8 (94.4) | 2014.8 (95.6) | 0.012 | 2438.8 (94.3) | 3558.1 (94.7) | 0.004 | 5458.7 (94.2) | 5808.7 (94.5) | 0.004 |
| **Race, (%)** |  |  |  |  |  |  |  |  |  |
| White, non-Hispanic | 1528.8 (51.3) | 1028.0 (48.8) | -0.026 | 1362.1 (52.7) | 2078.5 (55.3) | 0.027 | 3011.8 (52.0) | 3301.2 (53.7) | 0.018 |
| Black, non-Hispanic | 943.3 (31.7) | 686.9 (32.6) | 0.009 | 728.0 (28.2) | 984.7 (26.2) | -0.019 | 1759.4 (30.4) | 1731.6 (28.2) | -0.022 |
| Hispanic | 259.7 ( 8.7) | 212.2 (10.1) | 0.013 | 252.8 ( 9.8) | 355.2 ( 9.5) | -0.003 | 516.5 ( 8.9) | 577.9 ( 9.4) | 0.005 |
| Other | 149.9 ( 5.0) | 121.5 ( 5.8) | 0.007 | 159.1 ( 6.2) | 218.3 ( 5.8) | -0.003 | 317.7 ( 5.5) | 330.8 ( 5.4) | -0.001 |
| Unknown | 97.4 ( 3.3) | 59.7 ( 2.8) | -0.004 | 83.8 ( 3.2) | 119.0 ( 3.2) | -0.001 | 191.4 ( 3.3) | 202.9 ( 3.3) | 0.000 |
| **Phase (Admission Date) , (%)** |  |  |  |  |  |  |  |  |  |
| 1: June 7 - July 11 | 474.3 (15.9) | 273.5 (13.0) | -0.029 | 581.1 (22.5) | 602.7 (16.0) | -0.064 | 1077.2 (18.6) | 850.2 (13.8) | -0.047 |
| 2: July 12 - Aug. 15 | 515.4 (17.3) | 325.9 (15.5) | -0.018 | 538.5 (20.8) | 676.8 (18.0) | -0.028 | 1049.2 (18.1) | 1165.3 (19.0) | 0.009 |
| 3: Aug. 16 - Oct. 17 | 659.4 (22.1) | 483.1 (22.9) | 0.008 | 564.4 (21.8) | 772.6 (20.6) | -0.013 | 1260.0 (21.7) | 1290.7 (21.0) | -0.007 |
| 4: Oct. 18 - Dec. 5 | 1330.1 (44.6) | 1025.7 (48.6) | 0.040 | 901.7 (34.9) | 1703.6 (45.4) | 0.105 | 2410.3 (41.6) | 2838.0 (46.2) | 0.046 |
| **Site Dexamethasone Prescribing, (%)** |  |  |  |  |  |  |  |  |  |
| Low | 768.0 (25.8) | 365.1 (17.3) | -0.085 | 684.2 (26.5) | 719.1 (19.1) | -0.073 | 1477.9 (25.5) | 1227.7 (20.0) | -0.055 |
| Medium | 1811.7 (60.8) | 1379.7 (65.4) | 0.046 | 1510.0 (58.4) | 2236.0 (59.5) | 0.011 | 3565.1 (61.5) | 3705.7 (60.3) | -0.012 |
| High | 399.5 (13.4) | 363.5 (17.2) | 0.038 | 391.5 (15.1) | 800.5 (21.3) | 0.062 | 753.7 (13.0) | 1210.9 (19.7) | 0.067 |
| **Smoking Status, (%)** |  |  |  |  |  |  |  |  |  |
| Never Smoked | 1042.9 (35.0) | 761.9 (36.1) | 0.011 | 907.6 (35.1) | 1264.8 (33.7) | -0.014 | 2008.6 (34.7) | 2061.8 (33.6) | -0.011 |
| Former Smoker | 1149.4 (38.6) | 867.1 (41.1) | 0.025 | 1108.8 (42.9) | 1705.5 (45.4) | 0.025 | 2382.6 (41.1) | 2686.1 (43.7) | 0.026 |
| Current Smoker | 718.6 (24.1) | 452.5 (21.5) | -0.027 | 527.7 (20.4) | 721.5 (19.2) | -0.012 | 1315.7 (22.7) | 1275.6 (20.8) | -0.019 |
| Unknown | 68.3 ( 2.3) | 26.7 ( 1.3) | -0.010 | 41.6 ( 1.6) | 63.9 ( 1.7) | 0.001 | 89.8 ( 1.5) | 120.6 ( 2.0) | 0.004 |
| **AUDIT-C Score (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 1836.1 (61.6) | 1303.7 (61.8) | 0.002 | 1690.4 (65.4) | 2422.7 (64.5) | -0.009 | 3677.0 (63.4) | 3870.0 (63.0) | -0.004 |
| 1 – 3 | 599.9 (20.1) | 435.8 (20.7) | 0.005 | 579.4 (22.4) | 872.6 (23.2) | 0.008 | 1236.9 (21.3) | 1393.5 (22.7) | 0.013 |
| 4 – 7 | 211.4 ( 7.1) | 161.7 ( 7.7) | 0.006 | 118.1 ( 4.6) | 180.5 ( 4.8) | 0.002 | 351.7 ( 6.1) | 348.8 ( 5.7) | -0.004 |
| 8 + | 92.9 ( 3.1) | 53.8 ( 2.6) | -0.006 | 44.7 ( 1.7) | 59.2 ( 1.6) | -0.002 | 130.9 ( 2.3) | 118.7 ( 1.9) | -0.003 |
| Unknown | 238.9 ( 8.0) | 153.3 ( 7.3) | -0.007 | 153.1 ( 5.9) | 220.8 ( 5.9) | 0.000 | 400.2 ( 6.9) | 413.2 ( 6.7) | -0.002 |
| **Comorbidities** |  |  |  |  |  |  |  |  |  |
| Myocardial Infarction (%) | 247.1 ( 8.3) | 138.3 ( 6.6) | -0.017 | 230.3 ( 8.9) | 310.2 ( 8.3) | -0.006 | 491.5 ( 8.5) | 468.9 ( 7.6) | -0.008 |
| Congestive Heart Failure (%) | 558.7 (18.8) | 411.2 (19.5) | 0.008 | 642.6 (24.9) | 806.2 (21.5) | -0.034 | 1257.0 (21.7) | 1256.7 (20.5) | -0.012 |
| Cerebrovascular Disease (%) | 534.4 (17.9) | 332.8 (15.8) | -0.022 | 451.3 (17.5) | 626.0 (16.7) | -0.008 | 1005.1 (17.3) | 988.3 (16.1) | -0.013 |
| Dementia (%) | 517.0 (17.4) | 270.8 (12.8) | -0.045 | 375.2 (14.5) | 439.1 (11.7) | -0.028 | 904.3 (15.6) | 721.8 (11.7) | -0.039 |
| Chronic Obstructive Pulmonary Disease (%) | 706.3 (23.7) | 570.9 (27.1) | 0.034 | 824.1 (31.9) | 1226.3 (32.7) | 0.008 | 1517.3 (26.2) | 1889.6 (30.8) | 0.046 |
| Rheumatoid Arthritis (%) | 50.9 ( 1.7) | 22.5 ( 1.1) | -0.006 | 54.0 ( 2.1) | 70.8 ( 1.9) | -0.002 | 79.5 ( 1.4) | 87.7 ( 1.4) | 0.001 |
| Peptic ulcer (%) | 78.9 ( 2.6) | 46.9 ( 2.2) | -0.004 | 50.8 ( 2.0) | 87.9 ( 2.3) | 0.004 | 133.3 ( 2.3) | 135.0 ( 2.2) | -0.001 |
| Liver disease, mild (%) | 397.6 (13.3) | 272.8 (12.9) | -0.004 | 239.1 ( 9.2) | 350.7 ( 9.3) | 0.001 | 637.9 (11.0) | 624.3 (10.2) | -0.008 |
| Diabetes, Uncomplicated (%) | 1327.3 (44.6) | 972.6 (46.1) | 0.016 | 1264.4 (48.9) | 1834.9 (48.9) | 0.000 | 2707.6 (46.7) | 2862.2 (46.6) | -0.001 |
| Diabetes, Complicated (%) | 862.3 (28.9) | 578.4 (27.4) | -0.015 | 837.4 (32.4) | 1128.6 (30.0) | -0.023 | 1810.1 (31.2) | 1773.0 (28.9) | -0.024 |
| Hemi or para plegia (%) | 94.4 ( 3.2) | 49.0 ( 2.3) | -0.008 | 74.6 ( 2.9) | 85.3 ( 2.3) | -0.006 | 168.6 ( 2.9) | 148.6 ( 2.4) | -0.005 |
| Liver disease, moderate-severe (%) | 73.8 ( 2.5) | 63.9 ( 3.0) | 0.006 | 27.1 ( 1.0) | 42.5 ( 1.1) | 0.001 | 95.4 ( 1.6) | 98.0 ( 1.6) | -0.001 |
| Metastatic cancer (%) | 62.3 ( 2.1) | 23.3 ( 1.1) | -0.010 | 32.3 ( 1.3) | 63.3 ( 1.7) | 0.004 | 121.9 ( 2.1) | 115.1 ( 1.9) | -0.002 |
| HIV (%) | 39.4 ( 1.3) | 29.1 ( 1.4) | 0.001 | 39.0 ( 1.5) | 51.2 ( 1.4) | -0.001 | 70.3 ( 1.2) | 57.5 ( 0.9) | -0.003 |
| Renal disease (%) | 735.1 (24.7) | 537.2 (25.5) | 0.008 | 729.4 (28.2) | 964.6 (25.7) | -0.025 | 1567.4 (27.0) | 1560.7 (25.4) | -0.016 |
| **Charlson Comorbidities Count (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 621.0 (20.8) | 448.5 (21.3) | 0.004 | 485.5 (18.8) | 689.1 (18.3) | -0.004 | 1122.3 (19.4) | 1207.4 (19.7) | 0.003 |
| 1 - 2 | 920.5 (30.9) | 688.0 (32.6) | 0.017 | 733.7 (28.4) | 1184.0 (31.5) | 0.032 | 1767.9 (30.5) | 1953.9 (31.8) | 0.013 |
| 3 - 4 | 654.1 (22.0) | 456.2 (21.6) | -0.003 | 617.4 (23.9) | 913.0 (24.3) | 0.004 | 1327.6 (22.9) | 1481.3 (24.1) | 0.012 |
| 5 + | 783.5 (26.3) | 515.6 (24.5) | -0.018 | 749.1 (29.0) | 969.6 (25.8) | -0.032 | 1578.9 (27.2) | 1501.7 (24.4) | -0.028 |
| **Number of Doctors (prior year) (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 1276.8 (42.9) | 885.2 (42.0) | -0.009 | 985.6 (38.1) | 1430.6 (38.1) | 0.000 | 2330.1 (40.2) | 2475.4 (40.3) | 0.001 |
| 1 | 816.9 (27.4) | 627.3 (29.8) | 0.023 | 674.8 (26.1) | 1043.7 (27.8) | 0.017 | 1588.7 (27.4) | 1685.4 (27.4) | 0.000 |
| 2 - 4 | 812.5 (27.3) | 555.7 (26.4) | -0.009 | 850.5 (32.9) | 1196.5 (31.9) | -0.010 | 1717.9 (29.6) | 1835.7 (29.9) | 0.002 |
| 5 + | 72.9 ( 2.4) | 40.1 ( 1.9) | -0.005 | 74.8 ( 2.9) | 84.9 ( 2.3) | -0.006 | 160.0 ( 2.8) | 147.6 ( 2.4) | -0.004 |
| **Specialty clinics attended**  Cardiology **(%)** | 732.6 (24.6) | 531.3 (25.2) | 0.006 | 741.9 (28.7) | 1059.3 (28.2) | -0.005 | 1512.0 (26.1) | 1661.1 (27.0) | 0.010 |
| Coagulation (%) | 47.5 ( 1.6) | 46.8 ( 2.2) | 0.006 | 40.3 ( 1.6) | 49.8 ( 1.3) | -0.002 | 88.0 ( 1.5) | 93.8 ( 1.5) | 0.000 |
| Pacemaker (%) | 112.6 ( 3.8) | 115.5 ( 5.5) | 0.017 | 92.3 ( 3.6) | 115.7 ( 3.1) | -0.005 | 232.5 ( 4.0) | 220.8 ( 3.6) | -0.004 |
| Dialysis (%) | 34.9 ( 1.2) | 21.2 ( 1.0) | -0.002 | 70.4 ( 2.7) | 66.6 ( 1.8) | -0.010 | 98.7 ( 1.7) | 99.8 ( 1.6) | -0.001 |
| Gastoenterology (%) | 256.1 ( 8.6) | 175.1 ( 8.3) | -0.003 | 234.8 ( 9.1) | 368.2 ( 9.8) | 0.007 | 508.1 ( 8.8) | 586.5 ( 9.5) | 0.008 |
| Hepatology (%) | 105.7 ( 3.5) | 67.7 ( 3.2) | -0.003 | 77.4 ( 3.0) | 94.7 ( 2.5) | -0.005 | 183.2 ( 3.2) | 146.2 ( 2.4) | -0.008 |
| Homeless (%) | 231.8 ( 7.8) | 148.3 ( 7.0) | -0.007 | 127.0 ( 4.9) | 141.8 ( 3.8) | -0.011 | 376.3 ( 6.5) | 304.9 ( 5.0) | -0.015 |
| **Co-medications** |  |  |  |  |  |  |  |  |  |
| Prophylactic Anticoagulants | 1597.7 (53.6) | 1127.2 (53.5) | -0.002 | 1488.4 (57.6) | 2171.8 (57.8) | 0.003 | 3164.0 (54.6) | 3444.3 (56.1) | 0.015 |
| Remdesivir, 1st 48 hours (%) | 433.7 (14.6) | 439.7 (20.9) | 0.063 | 999.8 (38.7) | 2174.3 (57.9) | 0.192 | 1714.5 (29.6) | 2630.2 (42.8) | 0.132 |
| **Laboratory Results** |  |  |  |  |  |  |  |  |  |
| Albumin, g/dL (%) |  |  |  |  |  |  |  |  |  |
| 3.5 + | 1267.1 (42.5) | 770.3 (36.5) | -0.060 | 795.3 (30.8) | 1084.5 (28.9) | -0.019 | 2125.2 (36.7) | 2040.4 (33.2) | -0.035 |
| 3 - 3.49 | 924.4 (31.0) | 728.9 (34.6) | 0.035 | 878.8 (34.0) | 1348.7 (35.9) | 0.019 | 1871.1 (32.3) | 2103.8 (34.2) | 0.020 |
| < 3 | 622.6 (20.9) | 529.5 (25.1) | 0.042 | 811.5 (31.4) | 1199.6 (31.9) | 0.006 | 1527.9 (26.4) | 1775.3 (28.9) | 0.025 |
| Missing | 165.0 ( 5.5) | 79.6 ( 3.8) | -0.018 | 100.1 ( 3.9) | 122.9 ( 3.3) | -0.006 | 272.5 ( 4.7) | 224.8 ( 3.7) | -0.010 |
| Alanine aminotransferase, IU/L (%) |  |  |  |  |  |  |  |  |  |
| < 20 | 949.8 (31.9) | 596.0 (28.3) | -0.036 | 656.3 (25.4) | 853.0 (22.7) | -0.027 | 1678.7 (29.0) | 1532.1 (24.9) | -0.040 |
| 20 - 39 | 1155.8 (38.8) | 865.1 (41.0) | 0.022 | 1137.9 (44.0) | 1638.7 (43.6) | -0.004 | 2415.7 (41.7) | 2621.7 (42.7) | 0.010 |
| 40 + | 731.2 (24.5) | 613.5 (29.1) | 0.046 | 714.2 (27.6) | 1184.6 (31.5) | 0.039 | 1494.2 (25.8) | 1839.4 (29.9) | 0.042 |
| Missing | 142.3 ( 4.8) | 33.6 ( 1.6) | -0.032 | 77.2 ( 3.0) | 79.4 ( 2.1) | -0.009 | 208.1 ( 3.6) | 151.1 ( 2.5) | -0.011 |
| Asparate aminostransferase, IU/L (%) |  |  |  |  |  |  |  |  |  |
| < 20 | 699.1 (23.5) | 272.4 (12.9) | -0.105 | 331.1 (12.8) | 399.0 (10.6) | -0.022 | 1054.7 (18.2) | 829.8 (13.5) | -0.047 |
| 20 - 39 | 1372.6 (46.1) | 1075.9 (51.0) | 0.050 | 1166.3 (45.1) | 1679.2 (44.7) | -0.004 | 2670.2 (46.1) | 2816.1 (45.8) | -0.002 |
| 40 + | 907.4 (30.5) | 760.0 (36.0) | 0.056 | 1088.4 (42.1) | 1677.6 (44.7) | 0.026 | 2071.8 (35.7) | 2498.3 (40.7) | 0.049 |
| Creatinine, mg/dL (%) |  |  |  |  |  |  |  |  |  |
| < 1.2 | 1499.4 (50.3) | 967.2 (45.9) | -0.045 | 1108.0 (42.9) | 1704.5 (45.4) | 0.025 | 2671.7 (46.1) | 2857.0 (46.5) | 0.004 |
| 1.2 – 1.99 | 1035.8 (34.8) | 811.3 (38.5) | 0.037 | 992.1 (38.4) | 1432.2 (38.1) | -0.002 | 2141.5 (36.9) | 2265.1 (36.9) | -0.001 |
| 2 + | 432.9 (14.5) | 329.8 (15.6) | 0.011 | 485.6 (18.8) | 619.0 (16.5) | -0.023 | 983.5 (17.0) | 1022.1 (16.6) | -0.003 |
| Missing | 11.0 ( 0.4) | 0.0 ( 0.0) | -0.004 | 0.0 ( 0.0) | 0.0 ( 0.0) |  | 0.0 ( 0.0) | 0.0 ( 0.0) |  |
| Fibrosis-4 Index (%) |  |  |  |  |  |  |  |  |  |
| < 1.45 | 686.8 (23.1) | 439.5 (20.8) | -0.022 | 353.2 (13.7) | 569.2 (15.2) | 0.015 | 1065.6 (18.4) | 1062.8 (17.3) | -0.011 |
| 1.45 – 3.25 | 1204.6 (40.4) | 837.1 (39.7) | -0.007 | 1067.9 (41.3) | 1644.5 (43.8) | 0.025 | 2393.0 (41.3) | 2597.0 (42.3) | 0.010 |
| 3.25 + | 928.5 (31.2) | 798.1 (37.9) | 0.067 | 1083.7 (41.9) | 1456.9 (38.8) | -0.031 | 2101.8 (36.3) | 2325.3 (37.8) | 0.016 |
| Missing | 159.2 ( 5.3) | 33.6 ( 1.6) | -0.038 | 81.0 ( 3.1) | 85.1 ( 2.3) | -0.009 | 236.3 ( 4.1) | 159.1 ( 2.6) | -0.015 |
| Lactate, mmol/L (%) |  |  |  |  |  |  |  |  |  |
| 1\_1.2 | 493.0 (16.5) | 441.7 (21.0) | 0.044 | 455.4 (17.6) | 695.1 (18.5) | 0.009 | 1003.8 (17.3) | 1075.5 (17.5) | 0.002 |
| 2\_1.2LT2 | 682.6 (22.9) | 558.3 (26.5) | 0.036 | 713.6 (27.6) | 1170.2 (31.2) | 0.036 | 1510.3 (26.1) | 1816.4 (29.6) | 0.035 |
| 3\_GE2 | 348.1 (11.7) | 312.3 (14.8) | 0.031 | 385.0 (14.9) | 559.1 (14.9) | 0.000 | 737.4 (12.7) | 880.6 (14.3) | 0.016 |
| Missing | 1455.5 (48.9) | 796.0 (37.8) | -0.111 | 1031.7 (39.9) | 1331.3 (35.4) | -0.045 | 2545.2 (43.9) | 2371.8 (38.6) | -0.053 |
| Platelet count per microL (%) |  |  |  |  |  |  |  |  |  |
| 150 or higher | 2019.9 (67.8) | 1370.8 (65.0) | -0.028 | 1636.0 (63.3) | 2488.6 (66.3) | 0.030 | 3822.5 (65.9) | 4050.8 (65.9) | 0.000 |
| < 150 | 943.2 (31.7) | 737.4 (35.0) | 0.033 | 946.9 (36.6) | 1262.6 (33.6) | -0.030 | 1964.6 (33.9) | 2081.7 (33.9) | 0.000 |
| Missing | 16.0 ( 0.5) | 0.0 ( 0.0) | -0.005 | 2.9 ( 0.1) | 4.5 ( 0.1) | 0.000 | 9.6 ( 0.2) | 11.7 ( 0.2) | 0.000 |
| Total bilirubin, mg/dL (%) |  |  |  |  |  |  |  |  |  |
| < 1 | 2268.0 (76.1) | 1624.2 (77.0) | 0.009 | 1978.0 (76.5) | 2841.7 (75.7) | -0.008 | 4395.1 (75.8) | 4646.6 (75.6) | -0.002 |
| 1 - 1.2 | 218.7 ( 7.3) | 180.6 ( 8.6) | 0.012 | 228.2 ( 8.8) | 354.7 ( 9.4) | 0.006 | 489.1 ( 8.4) | 558.8 ( 9.1) | 0.007 |
| 1.2 + | 368.0 (12.4) | 281.1 (13.3) | 0.010 | 307.6 (11.9) | 487.2 (13.0) | 0.011 | 730.4 (12.6) | 808.8 (13.2) | 0.006 |
| Missing | 124.4 ( 4.2) | 22.3 ( 1.1) | -0.031 | 71.9 ( 2.8) | 72.2 ( 1.9) | -0.009 | 182.1 ( 3.1) | 130.1 ( 2.1) | -0.010 |
| White Blood Count per microL (%) |  |  |  |  |  |  |  |  |  |
| 4-10 | 1746.6 (58.6) | 1082.6 (51.3) | -0.073 | 1378.3 (53.3) | 1818.5 (48.4) | -0.049 | 3243.2 (55.9) | 3097.6 (50.4) | -0.055 |
| <4 | 803.4 (27.0) | 653.7 (31.0) | 0.040 | 769.2 (29.7) | 1095.3 (29.2) | -0.006 | 1622.3 (28.0) | 1776.7 (28.9) | 0.009 |
| >10 | 429.1 (14.4) | 372.0 (17.6) | 0.032 | 438.2 (16.9) | 841.9 (22.4) | 0.055 | 931.2 (16.1) | 1269.8 (20.7) | 0.046 |
| C-reactive protein measured (%) | 1689.4 (56.7) | 1364.5 (64.7) | 0.080 | 1550.1 (59.9) | 2386.3 (63.5) | 0.036 | 3428.1 (59.1) | 3883.6 (63.2) | 0.041 |
| D-dimer measured (%) | 2184.7 (73.3) | 1657.5 (78.6) | 0.053 | 2106.3 (81.5) | 3153.8 (84.0) | 0.025 | 4512.3 (77.8) | 4998.2 (81.3) | 0.035 |
| **Vital Signs** |  |  |  |  |  |  |  |  |  |
| Highest Temperature (F) (%) |  |  |  |  |  |  |  |  |  |
| < 99 | 1226.6 (41.2) | 832.8 (39.5) | -0.017 | 684.9 (26.5) | 1071.6 (28.5) | 0.020 | 1968.5 (34.0) | 2001.3 (32.6) | -0.014 |
| 99 - 100 | 735.0 (24.7) | 479.8 (22.8) | -0.019 | 542.6 (21.0) | 846.3 (22.5) | 0.015 | 1389.2 (24.0) | 1452.8 (23.6) | -0.003 |
| 100 - 102 | 693.4 (23.3) | 522.8 (24.8) | 0.015 | 869.7 (33.6) | 1231.0 (32.8) | -0.009 | 1601.0 (27.6) | 1769.6 (28.8) | 0.012 |
| 102 + | 314.2 (10.5) | 267.2 (12.7) | 0.021 | 478.5 (18.5) | 591.4 (15.7) | -0.028 | 818.1 (14.1) | 893.9 (14.5) | 0.004 |
| Missing | 9.8 ( 0.3) | 5.8 ( 0.3) | -0.001 | 9.9 ( 0.4) | 15.4 ( 0.4) | 0.000 | 19.9 ( 0.3) | 26.7 ( 0.4) | 0.001 |
| Mean Arterial Pressure, mmHg (%) |  |  |  |  |  |  |  |  |  |
| < 60 | 70.8 ( 2.4) | 53.4 ( 2.5) | 0.002 | 61.1 ( 2.4) | 72.9 ( 1.9) | -0.004 | 141.0 ( 2.4) | 118.5 ( 1.9) | -0.005 |
| 60 – 69 | 365.0 (12.3) | 205.2 ( 9.7) | -0.025 | 387.6 (15.0) | 509.2 (13.6) | -0.014 | 784.4 (13.5) | 751.0 (12.2) | -0.013 |
| 70 – 89 | 1954.5 (65.6) | 1416.8 (67.2) | 0.016 | 1721.5 (66.6) | 2531.4 (67.4) | 0.008 | 3812.6 (65.8) | 4141.8 (67.4) | 0.016 |
| 90 + | 582.2 (19.5) | 431.2 (20.5) | 0.009 | 407.1 (15.7) | 630.2 (16.8) | 0.010 | 1049.4 (18.1) | 1112.1 (18.1) | 0.000 |
| Missing | 6.6 ( 0.2) | 1.7 ( 0.1) | -0.001 | 8.5 ( 0.3) | 12.1 ( 0.3) | 0.000 | 9.3 ( 0.2) | 20.8 ( 0.3) | 0.002 |
| Lowest Oxygen Saturation (%) |  |  |  |  |  |  |  |  |  |
| < 88 | 43.0 ( 1.4) | 25.2 ( 1.2) | -0.002 | 245.8 ( 9.5) | 415.6 (11.1) | 0.016 | 312.7 ( 5.4) | 468.1 ( 7.6) | 0.022 |
| 88 - 92 | 887.9 (29.8) | 707.3 (33.6) | 0.037 | 1410.9 (54.6) | 2170.9 (57.8) | 0.032 | 2438.6 (42.1) | 3022.9 (49.2) | 0.071 |
| 93 - 95 | 1415.5 (47.5) | 997.6 (47.3) | -0.002 | 727.3 (28.1) | 896.6 (23.9) | -0.043 | 2191.5 (37.8) | 2006.9 (32.7) | -0.051 |
| 96 + | 564.1 (18.9) | 307.0 (14.6) | -0.044 | 156.6 ( 6.1) | 193.7 ( 5.2) | -0.009 | 733.5 (12.7) | 513.5 ( 8.4) | -0.043 |
| Missing | 68.6 ( 2.3) | 71.2 ( 3.4) | 0.011 | 45.1 ( 1.7) | 78.9 ( 2.1) | 0.004 | 120.3 ( 2.1) | 132.9 ( 2.2) | 0.001 |

**C. Propensity weighted pseudo population estimating the average treatment effect in the treated population (ATT)**

| Characteristics | No Oxygen | | | Nasal Canula | | | Combined Cohort | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| No | Yes | SMD | No | No | Yes | SMD | Yes | No |
| **Cohort, n** | 452.7 | 595.0 |  | 1638.9 | 2793.0 |  | 2200.7 | 3388.0 |  |
| **Age, (%)** |  |  |  |  |  |  |  |  |  |
| <50 | 39.7 ( 8.8) | 59.0 ( 9.9) | 0.011 | 138.8 ( 8.5) | 261.0 ( 9.3) | 0.009 | 177.4 ( 8.1) | 320.0 ( 9.4) | 0.014 |
| 50-59 | 60.0 (13.3) | 90.0 (15.1) | 0.019 | 192.7 (11.8) | 344.0 (12.3) | 0.006 | 262.4 (11.9) | 434.0 (12.8) | 0.009 |
| 60-69 | 113.7 (25.1) | 138.0 (23.2) | -0.019 | 360.3 (22.0) | 647.0 (23.2) | 0.012 | 496.8 (22.6) | 785.0 (23.2) | 0.006 |
| 70-79 | 150.3 (33.2) | 195.0 (32.8) | -0.004 | 611.7 (37.3) | 1048.0 (37.5) | 0.002 | 802.7 (36.5) | 1243.0 (36.7) | 0.002 |
| 80+ | 88.9 (19.6) | 113.0 (19.0) | -0.007 | 335.5 (20.5) | 493.0 (17.7) | -0.028 | 461.4 (21.0) | 606.0 (17.9) | -0.031 |
| **Sex: Male, (%)** | 430.0 (95.0) | 562.0 (94.5) | -0.005 | 1545.1 (94.3) | 2644.0 (94.7) | 0.004 | 2069.5 (94.0) | 3206.0 (94.6) | 0.006 |
| **Race, (%)** |  |  |  |  |  |  |  |  |  |
| White, non-Hispanic | 241.0 (53.2) | 321.0 (53.9) | 0.007 | 865.2 (52.8) | 1589.0 (56.9) | 0.041 | 1174.2 (53.4) | 1910.0 (56.4) | 0.030 |
| Black, non-Hispanic | 134.0 (29.6) | 159.0 (26.7) | -0.029 | 438.4 (26.7) | 678.0 (24.3) | -0.025 | 612.6 (27.8) | 837.0 (24.7) | -0.031 |
| Hispanic | 41.5 ( 9.2) | 61.0 (10.3) | 0.011 | 175.6 (10.7) | 290.0 (10.4) | -0.003 | 209.1 ( 9.5) | 351.0 (10.4) | 0.009 |
| Other | 22.8 ( 5.0) | 28.0 ( 4.7) | -0.003 | 104.0 ( 6.3) | 152.0 ( 5.4) | -0.009 | 140.7 ( 6.4) | 180.0 ( 5.3) | -0.011 |
| Unknown | 13.3 ( 2.9) | 26.0 ( 4.4) | 0.014 | 55.8 ( 3.4) | 84.0 ( 3.0) | -0.004 | 64.1 ( 2.9) | 110.0 ( 3.2) | 0.003 |
| **Phase (Admission Date) , (%)** |  |  |  |  |  |  |  |  |  |
| 1: June 7 - July 11 | 52.3 (11.6) | 51.0 ( 8.6) | -0.030 | 294.7 (18.0) | 270.0 ( 9.7) | -0.083 | 361.2 (16.4) | 321.0 ( 9.5) | -0.069 |
| 2: July 12 - Aug. 15 | 63.6 (14.1) | 79.0 (13.3) | -0.008 | 343.2 (20.9) | 490.0 (17.5) | -0.034 | 380.2 (17.3) | 569.0 (16.8) | -0.005 |
| 3: Aug. 16 - Oct. 17 | 100.9 (22.3) | 139.0 (23.4) | 0.011 | 368.3 (22.5) | 587.0 (21.0) | -0.015 | 457.7 (20.8) | 726.0 (21.4) | 0.006 |
| 4: Oct. 18 - Dec. 5 | 235.9 (52.1) | 326.0 (54.8) | 0.027 | 632.7 (38.6) | 1446.0 (51.8) | 0.132 | 1001.6 (45.5) | 1772.0 (52.3) | 0.068 |
| **Site Dexamethasone Prescribing, (%)** |  |  |  |  |  |  |  |  |  |
| Low | 79.3 (17.5) | 84.0 (14.1) | -0.034 | 392.3 (23.9) | 421.0 (15.1) | -0.089 | 481.9 (21.9) | 505.0 (14.9) | -0.070 |
| Medium | 290.3 (64.1) | 358.0 (60.2) | -0.040 | 964.2 (58.8) | 1665.0 (59.6) | 0.008 | 1353.7 (61.5) | 2023.0 (59.7) | -0.018 |
| High | 83.0 (18.3) | 153.0 (25.7) | 0.074 | 282.4 (17.2) | 707.0 (25.3) | 0.081 | 365.1 (16.6) | 860.0 (25.4) | 0.088 |
| **Smoking Status, (%)** |  |  |  |  |  |  |  |  |  |
| Never Smoked | 157.4 (34.8) | 203.0 (34.1) | -0.007 | 581.8 (35.5) | 939.0 (33.6) | -0.019 | 782.8 (35.6) | 1142.0 (33.7) | -0.019 |
| Former Smoker | 188.9 (41.7) | 269.0 (45.2) | 0.035 | 720.5 (44.0) | 1305.0 (46.7) | 0.028 | 979.9 (44.5) | 1574.0 (46.5) | 0.019 |
| Current Smoker | 99.6 (22.0) | 112.0 (18.8) | -0.032 | 323.2 (19.7) | 506.0 (18.1) | -0.016 | 415.3 (18.9) | 618.0 (18.2) | -0.006 |
| Unknown | 6.8 ( 1.5) | 11.0 ( 1.8) | 0.004 | 13.5 ( 0.8) | 43.0 ( 1.5) | 0.007 | 22.8 ( 1.0) | 54.0 ( 1.6) | 0.006 |
| **AUDIT-C Score (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 280.2 (61.9) | 369.0 (62.0) | 0.001 | 1068.2 (65.2) | 1767.0 (63.3) | -0.019 | 1413.4 (64.2) | 2136.0 (63.0) | -0.012 |
| 1 – 3 | 94.0 (20.8) | 132.0 (22.2) | 0.014 | 389.1 (23.7) | 674.0 (24.1) | 0.004 | 501.8 (22.8) | 806.0 (23.8) | 0.010 |
| 4 – 7 | 29.7 ( 6.6) | 34.0 ( 5.7) | -0.009 | 82.1 ( 5.0) | 147.0 ( 5.3) | 0.003 | 132.4 ( 6.0) | 181.0 ( 5.3) | -0.007 |
| 8 + | 11.9 ( 2.6) | 15.0 ( 2.5) | -0.001 | 24.6 ( 1.5) | 43.0 ( 1.5) | 0.000 | 29.9 ( 1.4) | 58.0 ( 1.7) | 0.004 |
| Unknown | 36.9 ( 8.1) | 45.0 ( 7.6) | -0.006 | 74.9 ( 4.6) | 162.0 ( 5.8) | 0.012 | 123.2 ( 5.6) | 207.0 ( 6.1) | 0.005 |
| **Comorbidities** |  |  |  |  |  |  |  |  |  |
| Myocardial Infarction (%) | 30.4 ( 6.7) | 36.0 ( 6.1) | -0.007 | 144.2 ( 8.8) | 216.0 ( 7.7) | -0.011 | 183.4 ( 8.3) | 252.0 ( 7.4) | -0.009 |
| Congestive Heart Failure (%) | 83.8 (18.5) | 102.0 (17.1) | -0.014 | 381.8 (23.3) | 534.0 (19.1) | -0.042 | 495.4 (22.5) | 636.0 (18.8) | -0.037 |
| Cerebrovascular Disease (%) | 66.4 (14.7) | 79.0 (13.3) | -0.014 | 271.0 (16.5) | 418.0 (15.0) | -0.016 | 344.9 (15.7) | 497.0 (14.7) | -0.010 |
| Dementia (%) | 47.8 (10.6) | 59.0 ( 9.9) | -0.007 | 207.7 (12.7) | 252.0 ( 9.0) | -0.036 | 268.3 (12.2) | 311.0 ( 9.2) | -0.030 |
| Chronic Obstructive Pulmonary Disease (%) | 118.9 (26.3) | 168.0 (28.2) | 0.020 | 530.1 (32.3) | 923.0 (33.0) | 0.007 | 615.9 (28.0) | 1091.0 (32.2) | 0.042 |
| Rheumatoid Arthritis (%) | 5.8 ( 1.3) | 9.0 ( 1.5) | 0.002 | 40.0 ( 2.4) | 49.0 ( 1.8) | -0.007 | 34.5 ( 1.6) | 58.0 ( 1.7) | 0.001 |
| Peptic ulcer (%) | 7.9 ( 1.7) | 9.0 ( 1.5) | -0.002 | 27.8 ( 1.7) | 55.0 ( 2.0) | 0.003 | 39.2 ( 1.8) | 64.0 ( 1.9) | 0.001 |
| Liver disease, mild (%) | 53.6 (11.8) | 66.0 (11.1) | -0.008 | 141.9 ( 8.7) | 265.0 ( 9.5) | 0.008 | 206.1 ( 9.4) | 331.0 ( 9.8) | 0.004 |
| Diabetes, Uncomplicated (%) | 207.8 (45.9) | 278.0 (46.7) | 0.008 | 806.5 (49.2) | 1369.0 (49.0) | -0.002 | 1072.6 (48.7) | 1647.0 (48.6) | -0.001 |
| Diabetes, Complicated (%) | 132.1 (29.2) | 168.0 (28.2) | -0.010 | 530.6 (32.4) | 819.0 (29.3) | -0.031 | 679.9 (30.9) | 987.0 (29.1) | -0.018 |
| Hemi or paraplegia (%) | 11.4 ( 2.5) | 10.0 ( 1.7) | -0.008 | 38.6 ( 2.4) | 52.0 ( 1.9) | -0.005 | 50.5 ( 2.3) | 62.0 ( 1.8) | -0.005 |
| Liver disease, moderate-severe (%) | 8.6 ( 1.9) | 9.0 ( 1.5) | -0.004 | 14.1 ( 0.9) | 32.0 ( 1.1) | 0.003 | 28.4 ( 1.3) | 41.0 ( 1.2) | -0.001 |
| Metastatic cancer (%) | 6.3 ( 1.4) | 6.0 ( 1.0) | -0.004 | 18.3 ( 1.1) | 46.0 ( 1.6) | 0.005 | 49.9 ( 2.3) | 52.0 ( 1.5) | -0.007 |
| HIV (%) | 7.4 ( 1.6) | 10.0 ( 1.7) | 0.000 | 26.9 ( 1.6) | 20.0 ( 0.7) | -0.009 | 27.3 ( 1.2) | 30.0 ( 0.9) | -0.004 |
| Renal disease (%) | 113.0 (25.0) | 140.0 (23.5) | -0.014 | 456.8 (27.9) | 656.0 (23.5) | -0.044 | 599.0 (27.2) | 796.0 (23.5) | -0.037 |
| **Charlson Comorbidities Count (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 92.5 (20.4) | 134.0 (22.5) | 0.021 | 314.0 (19.2) | 518.0 (18.5) | -0.006 | 426.0 (19.4) | 652.0 (19.2) | -0.001 |
| 1 - 2 | 150.2 (33.2) | 200.0 (33.6) | 0.004 | 469.4 (28.6) | 934.0 (33.4) | 0.048 | 692.5 (31.5) | 1134.0 (33.5) | 0.020 |
| 3 - 4 | 106.0 (23.4) | 131.0 (22.0) | -0.014 | 392.1 (23.9) | 702.0 (25.1) | 0.012 | 484.5 (22.0) | 833.0 (24.6) | 0.026 |
| 5 + | 104.1 (23.0) | 130.0 (21.8) | -0.011 | 463.4 (28.3) | 639.0 (22.9) | -0.054 | 597.7 (27.2) | 769.0 (22.7) | -0.045 |
| **Number of Doctors (prior year) (%)** |  |  |  |  |  |  |  |  |  |
| 0 | 185.8 (41.1) | 250.0 (42.0) | 0.010 | 604.6 (36.9) | 1075.0 (38.5) | 0.016 | 842.3 (38.3) | 1325.0 (39.1) | 0.008 |
| 1 | 138.4 (30.6) | 182.0 (30.6) | 0.000 | 440.5 (26.9) | 780.0 (27.9) | 0.010 | 610.1 (27.7) | 962.0 (28.4) | 0.007 |
| 2 - 4 | 121.6 (26.9) | 155.0 (26.1) | -0.008 | 549.1 (33.5) | 879.0 (31.5) | -0.020 | 683.3 (31.0) | 1034.0 (30.5) | -0.005 |
| 5 + | 6.9 ( 1.5) | 8.0 ( 1.3) | -0.002 | 44.7 ( 2.7) | 59.0 ( 2.1) | -0.006 | 65.0 ( 3.0) | 67.0 ( 2.0) | -0.010 |
| **Specialty clinics attended**  Cardiology **(%)** | 109.1 (24.1) | 147.0 (24.7) | 0.006 | 461.5 (28.2) | 759.0 (27.2) | -0.010 | 599.5 (27.2) | 906.0 (26.7) | -0.005 |
| Coagulation (%) | 9.5 ( 2.1) | 13.0 ( 2.2) | 0.001 | 20.2 ( 1.2) | 31.0 ( 1.1) | -0.001 | 30.0 ( 1.4) | 44.0 ( 1.3) | -0.001 |
| Pacemaker (%) | 15.2 ( 3.4) | 20.0 ( 3.4) | 0.000 | 45.2 ( 2.8) | 70.0 ( 2.5) | -0.002 | 81.6 ( 3.7) | 90.0 ( 2.7) | -0.011 |
| Dialysis (%) | 3.9 ( 0.9) | 5.0 ( 0.8) | 0.000 | 38.2 ( 2.3) | 33.0 ( 1.2) | -0.012 | 35.7 ( 1.6) | 38.0 ( 1.1) | -0.005 |
| Gastoenterology (%) | 41.7 ( 9.2) | 61.0 (10.3) | 0.010 | 150.7 ( 9.2) | 292.0 (10.5) | 0.013 | 216.0 ( 9.8) | 353.0 (10.4) | 0.006 |
| Hepatology (%) | 9.7 ( 2.2) | 10.0 ( 1.7) | -0.005 | 47.3 ( 2.9) | 64.0 ( 2.3) | -0.006 | 59.2 ( 2.7) | 74.0 ( 2.2) | -0.005 |
| Homeless (%) | 27.1 ( 6.0) | 30.0 ( 5.0) | -0.009 | 70.7 ( 4.3) | 93.0 ( 3.3) | -0.010 | 112.4 ( 5.1) | 123.0 ( 3.6) | -0.015 |
| **Co-medications** |  |  |  |  |  |  |  |  |  |
| Prophylactic Anticoagulants | 248.2 (54.8) | 332.0 (55.8) | 0.010 | 983.7 (60.0) | 1643.0 (58.8) | -0.012 | 1231.8 (56.0) | 1975.0 (58.3) | 0.023 |
| Remdesivir, 1st 48 hours (%) | 124.3 (27.5) | 257.0 (43.2) | 0.157 | 826.8 (50.4) | 2001.0 (71.6) | 0.212 | 1087.6 (49.4) | 2258.0 (66.6) | 0.172 |
| **Laboratory Results** |  |  |  |  |  |  |  |  |  |
| Albumin, g/dL (%) |  |  |  |  |  |  |  |  |  |
| 3.5 + | 174.5 (38.6) | 218.0 (36.6) | -0.019 | 498.7 (30.4) | 781.0 (28.0) | -0.025 | 677.5 (30.8) | 999.0 (29.5) | -0.013 |
| 3 - 3.49 | 151.9 (33.5) | 203.0 (34.1) | 0.006 | 551.1 (33.6) | 1005.0 (36.0) | 0.024 | 773.8 (35.2) | 1208.0 (35.7) | 0.005 |
| < 3 | 107.9 (23.8) | 151.0 (25.4) | 0.015 | 537.1 (32.8) | 928.0 (33.2) | 0.005 | 680.4 (30.9) | 1079.0 (31.8) | 0.009 |
| Missing | 18.4 ( 4.1) | 23.0 ( 3.9) | -0.002 | 51.9 ( 3.2) | 79.0 ( 2.8) | -0.003 | 69.0 ( 3.1) | 102.0 ( 3.0) | -0.001 |
| Alanine aminotransferase, IU/L (%) |  |  |  |  |  |  |  |  |  |
| < 20 | 129.5 (28.6) | 148.0 (24.9) | -0.037 | 370.4 (22.6) | 578.0 (20.7) | -0.019 | 540.9 (24.6) | 726.0 (21.4) | -0.031 |
| 20 - 39 | 187.3 (41.4) | 242.0 (40.7) | -0.007 | 737.3 (45.0) | 1201.0 (43.0) | -0.020 | 936.1 (42.5) | 1443.0 (42.6) | 0.001 |
| 40 + | 129.6 (28.6) | 199.0 (33.4) | 0.048 | 502.2 (30.6) | 977.0 (35.0) | 0.043 | 686.6 (31.2) | 1176.0 (34.7) | 0.035 |
| Missing | 6.3 ( 1.4) | 6.0 ( 1.0) | -0.004 | 29.1 ( 1.8) | 37.0 ( 1.3) | -0.004 | 37.1 ( 1.7) | 43.0 ( 1.3) | -0.004 |
| Asparate aminostransferase, IU/L (%) |  |  |  |  |  |  |  |  |  |
| < 20 | 61.7 (13.6) | 65.0 (10.9) | -0.027 | 139.2 ( 8.5) | 218.0 ( 7.8) | -0.007 | 225.0 (10.2) | 283.0 ( 8.4) | -0.019 |
| 20 - 39 | 218.0 (48.2) | 279.0 (46.9) | -0.013 | 741.6 (45.3) | 1218.0 (43.6) | -0.016 | 1025.4 (46.6) | 1497.0 (44.2) | -0.024 |
| 40 + | 172.9 (38.2) | 251.0 (42.2) | 0.040 | 758.1 (46.3) | 1357.0 (48.6) | 0.023 | 950.4 (43.2) | 1608.0 (47.5) | 0.043 |
| Creatinine, mg/dL (%) |  |  |  |  |  |  |  |  |  |
| < 1.2 | 206.5 (45.6) | 277.0 (46.6) | 0.009 | 700.3 (42.7) | 1324.0 (47.4) | 0.047 | 965.0 (43.9) | 1601.0 (47.3) | 0.034 |
| 1.2 – 1.99 | 179.4 (39.6) | 244.0 (41.0) | 0.014 | 632.4 (38.6) | 1048.0 (37.5) | -0.011 | 861.5 (39.1) | 1292.0 (38.1) | -0.010 |
| 2 + | 66.8 (14.8) | 74.0 (12.4) | -0.023 | 306.2 (18.7) | 421.0 (15.1) | -0.036 | 374.1 (17.0) | 495.0 (14.6) | -0.024 |
| Missing | 0.0 ( 0.0) | 0.0 ( 0.0) | 0.000 | 0.0 ( 0.0) | 0.0 ( 0.0) |  | 0.0 ( 0.0) | 0.0 ( 0.0) |  |
| Fibrosis-4 Index (%) |  |  |  |  |  |  |  |  |  |
| < 1.45 | 96.4 (21.3) | 129.0 (21.7) | 0.004 | 197.6 (12.1) | 411.0 (14.7) | 0.027 | 335.2 (15.2) | 540.0 (15.9) | 0.007 |
| 1.45 – 3.25 | 178.7 (39.5) | 239.0 (40.2) | 0.007 | 692.4 (42.2) | 1260.0 (45.1) | 0.029 | 878.7 (39.9) | 1499.0 (44.2) | 0.043 |
| 3.25 + | 171.1 (37.8) | 220.0 (37.0) | -0.008 | 718.1 (43.8) | 1081.0 (38.7) | -0.051 | 948.1 (43.1) | 1301.0 (38.4) | -0.047 |
| Missing | 6.6 ( 1.5) | 7.0 ( 1.2) | -0.003 | 30.8 ( 1.9) | 41.0 ( 1.5) | -0.004 | 38.7 ( 1.8) | 48.0 ( 1.4) | -0.003 |
| Lactate, mmol/L (%) |  |  |  |  |  |  |  |  |  |
| 1\_1.2 | 86.8 (19.2) | 118.0 (19.8) | 0.007 | 292.2 (17.8) | 496.0 (17.8) | -0.001 | 376.5 (17.1) | 614.0 (18.1) | 0.010 |
| 2\_1.2LT2 | 121.9 (26.9) | 172.0 (28.9) | 0.020 | 476.3 (29.1) | 930.0 (33.3) | 0.042 | 667.0 (30.3) | 1102.0 (32.5) | 0.022 |
| 3\_GE2 | 64.8 (14.3) | 96.0 (16.1) | 0.018 | 239.8 (14.6) | 413.0 (14.8) | 0.002 | 327.2 (14.9) | 509.0 (15.0) | 0.002 |
| Missing | 179.2 (39.6) | 209.0 (35.1) | -0.044 | 630.7 (38.5) | 954.0 (34.2) | -0.043 | 830.0 (37.7) | 1163.0 (34.3) | -0.034 |
| Platelet count per microL (%) |  |  |  |  |  |  |  |  |  |
| 150 or higher | 302.6 (66.8) | 401.0 (67.4) | 0.006 | 1046.9 (63.9) | 1893.0 (67.8) | 0.039 | 1391.4 (63.2) | 2294.0 (67.7) | 0.045 |
| < 150 | 150.1 (33.2) | 194.0 (32.6) | -0.006 | 590.1 (36.0) | 897.0 (32.1) | -0.039 | 807.6 (36.7) | 1091.0 (32.2) | -0.045 |
| Missing | 0.0 ( 0.0) | 0.0 ( 0.0) | 0.000 | 1.9 ( 0.1) | 3.0 ( 0.1) | 0.000 | 1.6 ( 0.1) | 3.0 ( 0.1) | 0.000 |
| Total bilirubin, mg/dL (%) |  |  |  |  |  |  |  |  |  |
| < 1 | 347.4 (76.7) | 456.0 (76.6) | -0.001 | 1272.7 (77.7) | 2089.0 (74.8) | -0.029 | 1653.3 (75.1) | 2545.0 (75.1) | 0.000 |
| 1 - 1.2 | 36.7 ( 8.1) | 49.0 ( 8.2) | 0.001 | 136.0 ( 8.3) | 278.0 (10.0) | 0.017 | 203.9 ( 9.3) | 327.0 ( 9.7) | 0.004 |
| 1.2 + | 64.2 (14.2) | 86.0 (14.5) | 0.003 | 202.5 (12.4) | 393.0 (14.1) | 0.017 | 311.5 (14.2) | 479.0 (14.1) | 0.000 |
| Missing | 4.4 ( 1.0) | 4.0 ( 0.7) | -0.003 | 27.7 ( 1.7) | 33.0 ( 1.2) | -0.005 | 32.1 ( 1.5) | 37.0 ( 1.1) | -0.004 |
| White Blood Count per microL (%) |  |  |  |  |  |  |  |  |  |
| 4-10 | 228.8 (50.5) | 274.0 (46.1) | -0.045 | 835.1 (51.0) | 1261.0 (45.1) | -0.058 | 1089.7 (49.5) | 1535.0 (45.3) | -0.042 |
| <4 | 136.0 (30.0) | 202.0 (33.9) | 0.039 | 508.8 (31.0) | 821.0 (29.4) | -0.016 | 692.9 (31.5) | 1023.0 (30.2) | -0.013 |
| >10 | 87.9 (19.4) | 119.0 (20.0) | 0.006 | 295.1 (18.0) | 711.0 (25.5) | 0.075 | 418.1 (19.0) | 830.0 (24.5) | 0.055 |
| C-reactive protein measured (%) | 313.0 (69.1) | 415.0 (69.7) | 0.006 | 1016.3 (62.0) | 1828.0 (65.4) | 0.034 | 1404.8 (63.8) | 2243.0 (66.2) | 0.024 |
| D-dimer measured (%) | 365.9 (80.8) | 486.0 (81.7) | 0.009 | 1366.2 (83.4) | 2354.0 (84.3) | 0.009 | 1817.9 (82.6) | 2840.0 (83.8) | 0.012 |
| **Vital Signs** |  |  |  |  |  |  |  |  |  |
| Highest Temperature (F) (%) |  |  |  |  |  |  |  |  |  |
| < 99 | 156.4 (34.6) | 198.0 (33.3) | -0.013 | 416.6 (25.4) | 816.0 (29.2) | 0.038 | 633.9 (28.8) | 1014.0 (29.9) | 0.011 |
| 99 - 100 | 114.2 (25.2) | 140.0 (23.5) | -0.017 | 325.2 (19.8) | 644.0 (23.1) | 0.032 | 491.0 (22.3) | 784.0 (23.1) | 0.008 |
| 100 - 102 | 126.3 (27.9) | 183.0 (30.8) | 0.029 | 562.0 (34.3) | 878.0 (31.4) | -0.029 | 695.5 (31.6) | 1061.0 (31.3) | -0.003 |
| 102 + | 52.9 (11.7) | 71.0 (11.9) | 0.002 | 327.2 (20.0) | 438.0 (15.7) | -0.043 | 368.4 (16.7) | 509.0 (15.0) | -0.017 |
| Missing | 2.8 ( 0.6) | 3.0 ( 0.5) | -0.001 | 7.9 ( 0.5) | 17.0 ( 0.6) | 0.001 | 11.9 ( 0.5) | 20.0 ( 0.6) | 0.001 |
| Mean Arterial Pressure, mmHg (%) |  |  |  |  |  |  |  |  |  |
| < 60 | 9.8 ( 2.2) | 9.0 ( 1.5) | -0.006 | 24.9 ( 1.5) | 46.0 ( 1.6) | 0.001 | 44.0 ( 2.0) | 55.0 ( 1.6) | -0.004 |
| 60 – 69 | 50.0 (11.1) | 51.0 ( 8.6) | -0.025 | 245.4 (15.0) | 341.0 (12.2) | -0.028 | 289.4 (13.2) | 392.0 (11.6) | -0.016 |
| 70 – 89 | 300.5 (66.4) | 401.0 (67.4) | 0.010 | 1106.5 (67.5) | 1906.0 (68.2) | 0.007 | 1477.4 (67.1) | 2307.0 (68.1) | 0.010 |
| 90 + | 91.8 (20.3) | 133.0 (22.4) | 0.021 | 254.6 (15.5) | 486.0 (17.4) | 0.019 | 386.6 (17.6) | 619.0 (18.3) | 0.007 |
| Missing | 0.6 ( 0.1) | 1.0 ( 0.2) | 0.000 | 7.5 ( 0.5) | 14.0 ( 0.5) | 0.000 | 3.3 ( 0.1) | 15.0 ( 0.4) | 0.003 |
| Lowest Oxygen Saturation (%) |  |  |  |  |  |  |  |  |  |
| < 88 | 6.7 ( 1.5) | 11.0 ( 1.8) | 0.004 | 175.8 (10.7) | 338.0 (12.1) | 0.014 | 179.7 ( 8.2) | 349.0 (10.3) | 0.021 |
| 88 - 92 | 170.9 (37.7) | 263.0 (44.2) | 0.065 | 950.6 (58.0) | 1686.0 (60.4) | 0.024 | 1157.8 (52.6) | 1949.0 (57.5) | 0.049 |
| 93 - 95 | 202.5 (44.7) | 238.0 (40.0) | -0.047 | 419.4 (25.6) | 580.0 (20.8) | -0.048 | 674.2 (30.6) | 818.0 (24.1) | -0.065 |
| 96 + | 59.1 (13.1) | 70.0 (11.8) | -0.013 | 65.2 ( 4.0) | 119.0 ( 4.3) | 0.003 | 148.4 ( 6.7) | 189.0 ( 5.6) | -0.012 |
| Missing | 13.6 ( 3.0) | 13.0 ( 2.2) | -0.008 | 28.0 ( 1.7) | 70.0 ( 2.5) | 0.008 | 40.6 ( 1.8) | 83.0 ( 2.4) | 0.006 |

**Supplemental Table 2. Sensitivity analyses estimating the average treatment effect in the treated population (ATT) in weighted Cox proportional hazards models for the association of corticosteroids with all-cause 90-day mortality among those not on IRS**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **No oxygen supplementation** | **Nasal cannula** | **Combined group: no oxygen plus NC** |
|  | **HR (95% CI)** | **HR (95% CI)** | **HR (95% CI)** |
| **Primary analysis** | 1.77 (1.25-2.50) | 1.26 (0.92-1.74) | 1.60 (1.24-2.08) |
| **Subgroup analyses** |  |  |  |
| Restricted to dexamethasone | 1.55 (0.95-2.52) | 1.28 (0.84-1.94) | 1.49 (1.02-2.18) |
| Excluding patients admitted to ICU in initial 48 hours | 1.62 (1.05-2.49) | 1.33 (0.88-1.99) | 1.60 (1.15-2.24) |
| Restricted to patients age 70 and older | 1.69 (1.13-2.54) | 1.49 (0.99-2.24) | 1.72 (1.24-2.40) |
| Models present the ATT (average treatment effect in treated population).  CI = confidence interval  HR = hazard ratio  IRS = intensive respiratory support | | | |

**Supplemental Table 3. Sensitivity analyses with unweighted, multivariable Cox proportional hazards regression models for the association of corticosteroids with all-cause 90-day mortality**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **No oxygen supplementation** | **Nasal cannula** | **Combined group: no oxygen plus NC** |
|  | **HR (95% CI)** | **HR (95% CI)** | **HR (95% CI)** |
| **Primary analysis** | 1.87 (1.36-2.57) | 1.39 (1.10-1.76) | 1.66 (1.39-1.99) |
| **Subgroup analyses** |  |  |  |
| Restricted to dexamethasone | 1.87 (1.32-2.66) | 1.37 (1.08-1.74) | 1.66 (1.38-1.99) |
| Excluding patients admitted to ICU in initial 48 hours | 1.85 (1.31-2.62) | 1.31 (1.01-1.69) | 1.63 (1.34-1.98) |
| Restricted to patients age 70 and older | 2.02 (1.40-2.89) | 1.41 (1.09-1.82) | 1.66 (1.36-2.02) |
| CI = confidence interval  HR = hazard ratio  IRS = intensive respiratory support | | | |

**Supplemental Table 4. STROBE Checklist of items for cohort studies**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Item No | Recommendation | Section/Paragraph |
| **Title and abstract** | 1 | (*a*) Indicate the study’s design with a commonly used term in the title or the abstract | Abstract: Methods |
| (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | Abstract: Methods, Findings, Interpretation |
| Introduction | | |  |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Introduction: Paragraphs 1-2 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Introduction: Paragraph 3 |
| Methods | | |  |
| Study design | 4 | Present key elements of study design early in the paper | Methods: Paragraph 1 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Methods: Paragraph 1 |
| Participants | 6 | (*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | Methods: Paragraphs 1-2 |
| (*b*)For matched studies, give matching criteria and number of exposed and unexposed | N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Methods: Paragraphs 3-6 |
| Data sources/ measurement | 8\* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Methods: Paragraphs 3-6 |
| Bias | 9 | Describe any efforts to address potential sources of bias | Methods: Paragraphs 7-8 |
| Study size | 10 | Explain how the study size was arrived at | All hospitalized COVID+ patients with at least 48h stay, concatenating length of stay to include emergency department/ observational status |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Methods: paragraphs 4, 6, Table 2, Supplemental Table 1 |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | Methods: paragraphs 7, 8 |
| (*b*) Describe any methods used to examine subgroups and interactions | Methods: paragraph 9 |
| (*c*) Explain how missing data were addressed | Methods: paragraph 8, Table 2, Supplemental Table 1 |
| (*d*) If applicable, explain how loss to follow-up was addressed | N/A |
| (*e*) Describe any sensitivity analyses | Methods: paragraph 9 |
| Results | | |  |
| Participants | 13\* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Methods: paragraph 1-2  Results: paragraph 1  Figure 1 |
| (b) Give reasons for non-participation at each stage | Methods: paragraph 2  Figure 1 |
| (c) Consider use of a flow diagram | Figure 1 |
| Descriptive data | 14\* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Results: paragraphs 1-2  Table 1 |
| (b) Indicate number of participants with missing data for each variable of interest | Table 2, Supplemental Table 1 |
| (c) Summarise follow-up time (eg, average and total amount) | Figure 2 |
| Outcome data | 15\* | Report numbers of outcome events or summary measures over time | Results: paragraph 2  Table 1, Figure 2, Figure 3 |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Results: paragraph 2  Results: paragraphs 4, 5  Table 3 |
| (*b*) Report category boundaries when continuous variables were categorized | Table 2 and Supplemental Table 1 |
| (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |  |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Results: paragraph 6 |
| Discussion | | |  |
| Key results | 18 | Summarise key results with reference to study objectives | Discussion: paragraph 1-2 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discussion: paragraph 7 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Discussion: paragraphs 1, 2, 3, 5, 6 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Discussion: paragraph 3, 4, 5, 6 |
| Other information | | |  |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Metadata |

\*Give information separately for exposed and unexposed groups.